logo
Home Publications About the Authors
About the Authors
Deutsch Englisch
Contact Impressum Data Protection Login
logo
Home Publications About the Authors
About the Authors
Deutsch Englisch
Contact Impressum Data Protection Login

KONTAKTINFORMATIONEN

 

Deutsches Arzneiprüfungsinstitut e. V. (DAPI)
Heidestraße 7
10557 Berlin
Tel. +49 30 / 40004-572
Fax +49 30 / 40004-573
Internet: www.dapi.de
E-Mail: info(at)dapi.de

Dr. Möhrke, Werner
Medical Department, Procter and Gamble Pharmaceuticals
Publications:
Switching from branded alendronate or risedronate to generic alendronate: effect on persistence with bisphosphonate therapy in Germany
Switching from branded alendronate or risedronate to generic alendronate: effect on persistence with bisphosphonate therapy in Germany
Beeinflusst die Umstellung von Risedronat oder Alendronat Originalprodukten auf Generika die Compliance (Persistenz)?
Effect of switching branded risedronate to branded or generic alendronate on medication compliance with weekly bisphosphonates: a cohort study utilizing the dapi prescription claims database
DAPI
News
Publications
Members